학술논문
Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD
Document Type
Article
Author
Edmonston, Daniel; Wojdyla, Daniel; Mehta, Rupal; Cai, Xuan; Lora, Claudia; Cohen, Debbie; Townsend, Raymond R.; He, Jiang; Go, Alan S.; Kusek, John; Weir, Matthew R.; Isakova, Tamara; Pencina, Michael; Wolf, Myles; Appel, Lawrence J.; Feldman, Harold I.; Lash, James P.; Rao, Panduranga S.; Rahman, Mahboob; Weir, Matthew R.; Lora, Claudia; Cohen, Debbie; Townsend, Raymond R.; He, Jiang; Go, Alan; Kusek, John
Source
American Journal of Kidney Diseases; December 2019, Vol. 74 Issue: 6 p771-781, 11p
Subject
Language
ISSN
02726386; 15236838
Abstract
An elevated fibroblast growth factor 23 (FGF-23) level is independently associated with adverse outcomes in populations with chronic kidney disease, but it is unknown whether FGF-23 testing can improve clinical risk prediction in individuals.